

An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease

ELIZABETH M. WRONE, JAMES L. ZEHNDER, JOHN M. HORNBERGER, LINDA M. McCANN, NORMAN S. COPLON, and STEPHEN P. FORTMANN

Satellite Research, Redwood City, and Stanford University School of Medicine, Department of Medicine, Stanford Center for Research in Disease Prevention, Palo Alto, California, USA

An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease.

Background. It is unclear whether total serum homocysteine (tHcy) and the C677T mutation of methylenetetrahydrofolate reductase (MTHFR) are associated with cardiovascular disease (CVD) in patients with end-stage renal disease (ESRD).

Methods. A cross-sectional sample of 459 patients with ESRD on chronic dialysis was assessed to determine whether tHcy and the C677T mutation are associated with CVD prevalence in multiple logistic regression. As CVD mortality is high, we examined the relationship between homozygosity and duration of dialysis.

Results. Mean tHcy was higher in patients without a history of CVD (35.2 $\mu\text{mol/L}$ vs. 30.4 $\mu\text{mol/L}$, $P = 0.02$). In multivariate models, CVD was negatively associated with tHcy and positively associated with TT genotype, male gender, and body mass index. Mean tHcy levels were higher among those with the TT genotype compared with those with the CC genotype when adjusted for age, folate, creatinine, and albumin (37.9 $\mu\text{mol/L}$ vs. 31.9 $\mu\text{mol/L}$, $P = 0.005$). Among whites, the prevalence of the TT genotype was higher in those having undergone less than one year of dialysis ($P = 0.002$).

Conclusions. The C677T genotype of MTHFR is associated with CVD in ESRD and may be a more meaningful marker than tHcy for abnormal homocysteine metabolism in ESRD. Prospective data from ongoing clinical trials are needed to improve our understanding of these findings. Screening for this polymorphism may help guide prevention measures.

Hyperhomocysteinemia is under intense investigation as a readily modifiable risk factor for cardiovascular disease (CVD) in the general population and in those with renal impairment. Despite homocysteine's role in vascular pathophysiology in vitro and animal studies, clinical

Key words: end-stage renal disease, methylenetetrahydrofolate reductase, C677T genotype, hyperhomocysteinemia, folate depletion, vascular pathophysiology, blood pressure, dialysis.

Received for publication August 24, 2000

and in revised form March 29, 2001

Accepted for publication April 10, 2001

© 2001 by the International Society of Nephrology

and epidemiologic evidence is mixed, and the lack of clinical trials leaves the question of causality open. There is less evidence concerning the relationship between total serum homocysteine (tHcy) [1] and cardiovascular risk in the subset of patients with end-stage renal disease (ESRD) than there is in the general population.

A common variant of a key enzyme in homocysteine metabolism, the C677T mutation (also known as the thermolabile variant) of methylenetetrahydrofolate reductase (MTHFR), located on chromosome 21, is emerging as a possible genetic contributor to hyperhomocysteinemia and CVD. The C677T point mutation of MTHFR results in a valine substitution for alanine [2]. With two copies of this variant (TT), serum activity of MTHFR is reduced to 30%, while serum activity of heterozygotes (CT) is 65% of that of wild-type (CC) individuals [2]. Epidemiologic evidence supports an influence of C677T genotype on homocysteine metabolism for those with relatively reduced folate levels [3–5], and this is mildly and less consistently so for the general population [3, 6]. The C677T mutation also may influence tHcy levels in ESRD, especially in those with low folate levels [7, 8]. The role of the C677T mutant allele in increasing the risk for vascular disease was unconfirmed in large studies [3, 9], a recent meta-analysis [6], and was not found in a study of 545 Japanese hemodialysis patients [7]. While it appears that the C677T mutation of the *MTHFR* gene may influence tHcy levels, especially in folate depletion, its role in hyperhomocysteinemia and CVD is unclear.

Patients with ESRD have levels of tHcy that are three times those of the general population [10]. Despite a strong, positive relationship between serum creatinine and tHcy [11], the mechanism of hyperhomocysteinemia in renal failure appears to operate through the inhibitory effect of putative uremic factors on enzymes in the folate-homocysteine pathway [12]. It appears to be unrelated to reduced renal clearance as renal failure progresses [13]. Because patients with ESRD have a crude mortality rate of 24%, half of which is due to CVD [14], improved

understanding of tHcy and cardiovascular risk may lead to the development of treatment and prevention strategies.

We undertook an investigation of tHcy and the C677T mutation of MTHFR in the pathogenesis of CVD. This report is a cross-sectional analysis of baseline entry data from a randomized prospective clinical trial of tHcy reduction in ESRD patients. The questions addressed in this article are as follows: (1) Is tHcy associated with CVD in this population? (2) What factors influence the tHcy level? (3) Is the C677T variant of MTHFR associated with elevated tHcy, CVD, and survival on dialysis?

METHODS

Study population

This analysis represents the findings of the baseline entry exam to a clinical trial, after informed consent and prior to initiation of any study procedures or treatments. The clinical trial was a randomized, standard-therapy controlled study of high-dose folic acid for the reduction of tHcy with clinical outcomes as end points. We studied 459 prevalent patients with ESRD undergoing chronic dialysis treatment (430 hemodialysis and 29 peritoneal dialysis) at 10 affiliated nonprofit outpatient units in northern California from March 1998 to May 1999. Adult patients who were undergoing hemodialysis or peritoneal dialysis and who were able to participate in the consent process were eligible for the study. Patients who were undergoing intradialytic parenteral nutrition, anticipating a living-related kidney transplant, receiving an anti-seizure medication, or were terminally ill were excluded from the study. A written consent was obtained from every patient after a full explanation of the study, which was approved by the Administrative Panel on Human Subjects in Medical Research of Stanford University. At the time that these data were gathered, the participants had not received instructions to change their pattern of folic acid or multivitamin use. CVD was defined as being present if there was a history of coronary artery intervention, myocardial infarction, stroke, transient ischemic attack, carotid end-arterectomy, or other clinical evidence of CVD, as documented in hospital discharge summaries or history and physical examination upon admission to the dialysis unit.

Baseline clinical variables were collected at the time of enrollment. These included diabetes status; smoking history; duration of renal replacement therapy; prescribed medication use, including dose and formulation of all vitamin supplements; height; and dry weight (the prescribed, postdialysis weight). Race was assigned from one of the following categories: African American, Asian/Pacific Islander, other/multiracial, or white. Patients were assigned a separate ethnic status that included Hispanic or non-Hispanic. Patients from four facilities were further assessed for compliance with prescribed vitamin use and

for over-the-counter vitamin supplement intake. For those on hemodialysis, the following were collected: vascular access history and predialysis and post-dialysis systolic and diastolic blood pressure (averaged over 9 treatments). In addition, the most recently monthly dialysis adequacy parameters were collected for all hemodialysis subjects. Adequacy parameters included Kt/V, a unit-less measure of dialysis dose, and normalized protein catabolic rate (nPCR). This kinetic modeling was single-pool, variable-volume urea using predialysis and post-dialysis blood urea nitrogen (BUN) assessment. The predialysis blood sample was taken prior to the initiation of dialysis and administration of saline or heparin. The post-dialysis sample was taken from the arterial port closest to the patient using the slow flow technique (within 15 to 30 seconds with the blood flow rate decreased to between 50 to 100 mL/min).

Biochemical assays

All patients had predialysis study blood samples drawn in conjunction with routine monthly specimens. tHcy concentrations were determined by high-performance liquid chromatography (HPLC) of serum specimens by Quest Diagnostics (San Diego, CA, USA). Normal values by this method are 2.8 to 13.5 $\mu\text{mol/L}$. Serum folate was determined using an ion capture assay that remains linear up to 20 ng/mL. Specimens with levels higher than 20 ng/mL were diluted. The normal range for serum folate was 3.1 to 12.4 ng/mL. Vitamin B₁₂ determination was performed using standard clinical diagnostic techniques by Quest Diagnostics. The normal range for vitamin B₁₂ was 200 to 1100 pg/mL. Total cholesterol, albumin, urea, creatinine, pre-albumin, phosphorus, glucose, and triglyceride determinations were performed at Satellite Laboratory Services, Inc., as part of the routine monthly care. Identification of the C677T translocation was performed using *HinfI* digestion and polymerase chain reaction (PCR) amplification from specimens of peripheral blood lymphocytes as described by Frosst et al [2]. PCR analysis was performed in the Molecular Diagnosis Laboratory (Department of Pathology, Stanford University Medical Center, Palo Alto, CA, USA).

Statistical methods

Correlations between continuous variables were tested with Pearson's correlation coefficient. Chi-square tests and analysis of variance were used to test relationships concerning dichotomous variables. The Student *t* test was used for testing involving means of distributions. The distribution of genotypes was assessed for conformation to the Hardy-Weinberg equilibrium by chi-square analysis as described by Emery [15]. Logistic regression was used to identify independent predictors of CVD and multiple linear regression was used to identify independent relationships to tHcy. All data analyses were performed using the SAS Systems version 6.1.2 software

Table 1. Characteristics of study cohort

Variable	No cardiovascular disease N = 303	Cardiovascular disease N = 156	P
Demographics			
Age years	58.8 ± 16.0	63.6 ± 12.6	0.001
Male %	42.9	64.1	0.001
Race/ethnicity = white ^a %	66.7	70.5	0.40
Diabetic %	44.2	48.1	0.43
Duration of dialysis years	3.9 ± 4.7	3.5 ± 4.0	0.28
Body mass index kg/m ²	26.6 ± 6.4	24.7 ± 5.3	0.002
Current smokers %	9.9	12.8	0.34
Past smokers %	30.4	42.3	0.01
Laboratory assessments			
Serum folate nmol/L	20.0 ± 14.1 (302)	21.8 ± 15.6 (155)	0.22
Vitamin B ₁₂ pg/mL	715 ± 635 (302)	644 ± 298 (153)	0.19
Serum creatinine mg/dL	9.1 ± 3.2	8.7 ± 2.7	0.18
Serum albumin mg/dL	3.97 ± 0.36	4.00 ± 0.31	0.43
Pre-albumin mg/dL	31.3 ± 7.7	32.2 ± 8.2	0.24
Serum cholesterol mg/dL	178 ± 42.4	174 ± 41.9	0.38
TT genotype C677T variant MTHFR %	9.2	19.9	0.001
CT genotype C677T variant MTHFR %	42.6	35.3	0.13
Homocysteine μmol/L	35.2 ± 24.0	30.4 ± 12.9	0.02
Homocysteine ^b μmol/L	34.6	31.5	0.0001
Hemodialysis patients, N = 430			
Systolic blood pressure ^c mm Hg	157 ± 21.0	153 ± 19.3	0.06
Diastolic blood pressure ^c mm Hg	80.5 ± 12.5	76.3 ± 11.0	0.0009
Kt/V ^d N = 428	1.55 ± 0.47	1.63 ± 0.51	0.10
NPCR ^e g/kg, N = 428	0.93 ± 0.23	1.00 ± 0.30	0.01

The number of subjects is in parentheses.

^aIncludes both non-Hispanic and Hispanic whites

^bAdjusted for age, gender, and body mass index

^cPredialysis, averaged over 9 treatments

^dKt/V is a unit-less measure of dialysis dose

^eNPCR is normalized protein catabolic rate

program. Results are reported as mean ± SD, except where otherwise indicated.

RESULTS

Subjects

The mean age of the patients (230 males and 229 females) was 60.4 ± 15.1 years. The racial/ethnic groups represented were 186 non-Hispanic white, 137 Hispanic (126 of whom were Hispanic-white), 71 Asian/Pacific Islanders, 54 African American, and 11 other/multiracial. Etiology of ESRD was diabetes type I (5.4%), diabetes type II (35.4%), hypertension/large vessel disease/cardiac (24.6%), glomerulonephritis (18.1%), secondary glomerulonephritis (3.1%), interstitial/pyelonephritis (5.2%), cystic/hereditary/congenital (4.6%), neoplasms (0.4%), miscellaneous (2.0%), and etiology uncertain or unknown (2.2%).

The clinical characteristics of the cohort with respect to the presence of CVD are described in Table 1. Mean tHcy was significantly higher in patients without a history of CVD (35.2 μmol/L ± 24.0) as compared with those with a history of CVD (30.4 μmol/L ± 12.9, *P* = 0.02). Patients with CVD were of older age, smaller size, and higher nPCR. The duration of dialysis, vitamin B₁₂ levels, folate levels, pre-albumin, cholesterol, creatinine, phos-

phorus, and glucose were not significantly different. One hundred fifty-six patients had at least one cardiovascular procedure or event, including coronary artery bypass graft, percutaneous transluminal coronary angioplasty, previous myocardial infarction, stroke, or carotid endarterectomy. These patients are listed by individual event: coronary artery bypass graft (54), previous myocardial infarction (54), percutaneous coronary intervention (24), stroke (37), and carotid endarterectomy (9). There were 50 patients with at least one limb or partial limb amputation. tHcy was higher in males than in females (34.9 ± 25.0 vs. 32.2 ± 16.0 μmol/L, *P* = 0.17), although this was not a statistically significant finding. Diabetics and nondiabetics had similar tHcy levels.

Characteristics by C677T mutation of MTHFR genotype

There were 59 patients with two copies (TT) of the allele, 184 with one copy (CT), and 216 with the wild-type allele (CC). This distribution did not vary significantly from the expected frequencies (49.7 TT, 202.6 CT, 206.7 CC) of these genotypes based on a Hardy-Weinberg equilibrium ($\chi^2 = 3.89$, degrees of freedom 2, *P* = 0.14). There were very few copies of the thermolabile variant in nonwhite ethnic groups. Three Asian patients, as well as one African American patient, were

Table 2. Clinical characteristics by C677T variant of MTHFR

	TT N = 59	CT N = 184	CC N = 216	P
Age years	63.6 ± 13.4	61.2 ± 14.5	59.0 ± 15.8	0.08
Age initiation ESRD years	60.1 ± 15.7	57.4 ± 16.4	55.1 ± 17.4	0.10
Age initiation ESRD years, non-white ^a	48.2 ± 19.6 (N = 4)	56.8 ± 17.1 (N = 40)	53.3 ± 17.0 (N = 103)	0.42
Male %	62.7 ^d	53.3	44.0	0.02
Race/ethnicity = white ^a %	93.2 ^d	78.2 ^d	52.3	0.0001
Diabetic %	55.9	45.7	42.6	0.19
Duration dialysis years	3.5 ± 4.8	3.8 ± 4.5	3.9 ± 4.3	0.81
Serum folate nmol/L	20.5 ± 12.1	20.3 ± 14.1	20.9 ± 15.8 (214)	0.93
Vitamin B ₁₂ pg/L	618 ± 319 (56)	658 ± 418 (183)	740 ± 674 (214)	0.18
Serum creatinine mg/dL	8.3 ± 3.1 ^d	8.7 ± 2.7 ^d	9.3 ± 3.2	0.01
Serum albumin mg/dL	3.96 ± 0.4	3.98 ± 0.3	3.99 ± 0.3	0.83
Homocysteine μmol/L	37.9 ± 16.8	34.1 ± 43.5	31.9 ± 13.5	0.14
Homocysteine ^b μmol/L	39.4 ^c	34.4	31.4	0.0001
Cardiovascular disease %	52.5 ^{df}	29.9	32.4	0.005
Cardiovascular disease ^c %	49.0 ^{df}	29.0	34.0	0.0001

ESRD is end-stage renal disease.

^aIncludes both non-Hispanic and Hispanic whites

^bAdjusted for age, folate, creatinine, and albumin

^cAdjusted for age, race/ethnicity, and gender

^dComparison with CC genotype significant at the 0.05 level by Bonferroni *t* test for multiple comparisons

^eComparison with CC genotype significant at the <0.005 level by Bonferroni *t* test for multiple comparisons

^fComparison with CT genotype significant at the 0.05 level by Bonferroni *t* test for multiple comparisons

homozygous for the mutation. There were six patients with the CT genotype in the other/multiracial group and five with the CC genotype. Hispanics as a group had a higher representation of heterozygotes and homozygotes than non-Hispanic whites. TT genotype comprised 23.4% for Hispanics and 12.4% for non-Hispanic whites ($\chi^2 = 9.0$, degrees of freedom 2, $P = 0.01$).

Table 2 shows the clinical characteristics of the three genotypes. The genotypes were similar with respect to age, age at initiation of dialysis, duration of dialysis, folate, and albumin. When adjusted for age, folate, creatinine, and albumin, tHcy levels were significantly higher in the TT group than in the CC group (39.4 μmol/L in TT vs. 31.4 μmol/L in CC at the <0.005 level by the Bonferroni *t* test for multiple comparisons). The genotypes differed with respect to creatinine and percentage of males. The TT genotype had a significantly higher prevalence of CVD than either the CT or CC genotypes (52.5 vs. 29.9 and 32.4%, respectively, $P = 0.05$ by the Bonferroni *t* test for multiple comparisons). This relationship persisted after adjustment for age, race, and gender. The effect of the TT genotype under conditions of below median folate status is illustrated in Figure 1. The study group was divided in two groups based on folate levels (above and below the median level of 17.6 mg/L).

Concomitant vitamin and folate use

Of the 459 patients, 80% were prescribed a supplement containing folic acid, vitamin B₆, and vitamin B₁₂. At four facilities representing 206 patients, we obtained further concomitant vitamin information. Of these 206, 80% of patients prescribed a folic acid-containing sup-




Fig. 1. Relationship between low-folate status and total serum homocysteine (tHcy) stratified by genotype. Low folate was defined as below the median folate level (less than 17.6 mg/mL; ▨). Mean tHcy levels are shown with standard error bars for each genotype. There were no significant differences in tHcy among the genotypes in the above-median folate group (■). There was an effect of genotype on tHcy in the below median folate group ($P = 0.01$). This effect persisted when adjusting for age, creatinine, and albumin. The asterisk refers to significant difference compared with the CC genotype in the below median folate group at the 0.05 level using the Bonferroni analysis of multiple comparisons.

plement were at least partially compliant (taken at least once in past 2 weeks), and 18% of patients not prescribed a folic acid-containing supplement were taking at least one folic acid-containing supplement. Brand name, dose, and actual dosing frequency were obtained on all 206, and the mean total daily amounts were as follows: folic acid 0.67 mg, vitamin B₆ 7.27 mg, and vitamin B₁₂ 5.52 μg.

Table 3. Correlation of homocysteine with continuous variables (Pearson correlation coefficients for homocysteine)

Variable	Rho	P
Age	-0.20	0.0001
Duration of dialysis	0.12	0.009
Body mass index kg/m^2	0.19	0.0001
Folate, serum, $N = 457$	-0.21	0.0001
Vitamin B ₁₂ , serum, $N = 455$	-0.12	0.009
Creatinine	0.33	0.0001
Albumin	0.27	0.0001
Prealbumin	0.12	0.009
Cholesterol	0.04	0.36
Kt/V, $N = 428$	-0.18	0.0002
NPCR, $N = 428$	0.13	0.008
Folic acid, daily intake, $N = 206$	-0.33	0.0001
Vitamin B ₆ , daily intake, $N = 206$	-0.33	0.0001
Vitamin B ₁₂ , daily intake, $N = 206$	-0.26	0.0002

Kt/V is a unit-less measure of dialysis dose and NPCR is normalized protein catabolic rate.

Table 4. Logistic regression for cardiovascular disease prevalence

Predictor variables	Odds ratio ^a	95% Confidence interval		P
		Lower	Upper	
Intercept	—	—	—	0.0001
Gender (male = 0)	0.40	0.26	0.62	0.0001
Body mass index	0.94	0.90	0.98	0.003
Blood pressure ^b	0.97	0.95	0.99	0.0009
TT versus not TT	2.39	1.29	4.44	0.006
tHcy	0.98	0.97	1.00	0.04

Age, race, cholesterol, albumin, diabetes, CT-genotype, past and current smoking, and prealbumin were removed by backward selection.

^aFor one-unit incremental increase

^bPredialysis diastolic blood pressure

Prediction of tHcy

Univariate analysis of tHcy is shown in Table 3, which presents the Pearson correlation coefficients of several clinical variables. tHcy had a strongly positive correlation to creatinine and albumin and a strongly negative correlation to age, folate, and daily intake of folic acid, vitamin B₆, and vitamin B₁₂. There were milder associations between tHcy and duration of dialysis, body mass index, vitamin B₁₂ level, and pre-albumin.

In multiple linear models for prediction of tHcy values, homozygosity for the C677T mutation, albumin, creatinine, and an interaction term for folate and genotype were strong, independent predictors. Body mass index, vitamin B₁₂ level, and folate level were weaker independent predictors. Age, gender, and actual daily intake amounts of folic acid, vitamin B₆, and B₁₂ dropped out of models.

Cardiovascular disease

The presence of CVD was independently predicted by gender (female protective), body mass index (negatively), predialysis diastolic blood pressure (negatively)




Fig. 2. Proportion of study patients by dialysis year. Dialysis year is the year-subgroup of duration of dialysis. The asterisk refers to those groups identified as statistically different from year 1 ($P = 0.0001$, controlling for age, race/ethnicity, gender, and diabetes).

tHcy (negatively), and the TT genotype in a model that removed age, race, cholesterol, albumin, diabetes, CT genotype, past and current smoking, and pre-albumin by backward selection. In addition, a yes/no term for concomitant vitamin intake was examined and was eliminated by backward selection from models (Table 4).

Relationship of MTHFR status to duration of dialysis

The mutant allele frequency and the percentage of homozygotes were lower in those with duration of dialysis of greater than one year (Fig. 2). This was statistically significant for non-Hispanic whites (25% compared with 8%, $P = 0.002$). Among Hispanics with less than one-year duration of dialysis, the TT genotype prevalence was 36% compared with 20% for those with greater than one-year duration of dialysis ($P = 0.13$).

DISCUSSION

In this cross-sectional analysis of 459 dialysis patients, patients with a history of CVD had lower levels of tHcy than those without a history of CVD. This negative relationship persisted in multivariate analysis when controlling for predictors of CVD, such as age, gender, and body mass index. However, the TT genotype was associated with prevalent CVD, even after adjustment for other cardiovascular risk factors, including tHcy, and was associated with duration of dialysis in non-Hispanic whites. Consistent with other investigations in the general population and ESRD, an association of the TT genotype and tHcy was found among those in the lower half of the folate distribution.

There are several reasonable explanations for the inverse association between tHcy and CVD and for the association of the TT genotype with CVD observed in this cross-sectional analysis. First, a single determination

of tHcy in ESRD, as measured in a cross-sectional study, may not represent lifetime tHcy exposure. During the years prior to the development of ESRD, tHcy was likely lower than the tHcy measured after dialysis was initiated. Historical tHcy determinations are required to assess the relationship to evolving CVD. However, the presence of genetic polymorphisms, such as the C677T variant of MTHFR, remains constant over a lifespan and can suggest a lifetime of abnormal homocysteine metabolism. Our data support the association of the homozygous C677T variant of MTHFR and CVD. This implies that C677T genotype may be a better predictor of CVD in ESRD than a single measurement of tHcy.

Second, methodological limitations constrain the interpretation of findings from cross-sectional analyses. For studies of ESRD patients, this is particularly relevant due to survivor bias from high mortality rates. Survivor bias can potentially exert a strong influence on both cross-sectional studies and clinical trials during the course of dialysis, especially when patients are enrolled with varying degrees of duration of dialysis. Ideally, clinical studies include patients from the same duration of dialysis cohort, that is, recent initiators and attempt to control for differences in residual renal function. Survival to the clinical state of ESRD may in and of itself impart a different risk profile, as patients with chronic renal insufficiency (and possibly the most adverse homocysteine metabolism) succumb to CVD. Additional methodologic explanations for reversal of association include error of tHcy measurement and CVD assessment. Possible specimen collection errors include failure to spin within 30 minutes or a failure to refrigerate. This seems unlikely, since the mean levels are very similar to other studies. tHcy assessment was done using a commercial HPLC assay that is well established. With respect to using clinical records for the assessment of CVD, we are likely overlooking cases of atherosclerotic disease in this population as most patients would have pathologic findings revealed by further clinical tests or autopsy.

Third, there may be a strong nutritional component driving the relationship between tHcy and comorbidity in ESRD due to the influence of serum albumin and dietary protein intake on tHcy levels. This observation is supported by similar findings in a recent cross-sectional study of 117 hemodialysis patients [16]. In that study, tHcy levels were dependent on nutritional status, protein intake, and serum albumin, and patients with CVD had lower tHcy levels as well as a higher prevalence of malnutrition and hypoalbuminemia than those without CVD. Furthermore, tHcy rises during treatment of malnourished patients with an amino acid-containing peritoneal dialysate (1.7 g methionine/day or half-normal intake) [17]. The presence of chronic inflammation further complicates the relationship by suppressing serum albumin, an important binding site for tHcy, and by contributing

to CVD [18]. While in the univariate analyses in this study tHcy correlated with serum albumin, pre-albumin, and body mass index, there was no evidence that those with CVD possessed a worse nutritional status than those without CVD. Inflammatory markers were not measured in our study. If nutritional or inflammatory status does play a role in the reverse association between tHcy and CVD prevalence, we were unable to detect it in this cross-sectional analysis.

Fourth, the phenomenon of an established risk factor in the general population having a markedly different if not opposite pattern in ESRD is not unique to our data. Blood pressure, body size, and serum cholesterol are well-established factors in the general population associated with increasing cardiovascular risk [19, 20], whereas in ESRD, there is a dramatically different picture. Blood pressure tends to have a “U”-shaped relationship with mortality [21], while body size and cholesterol have an inverse relationship [22, 23]. This does not mean that the forces of vascular pathophysiology are different in ESRD, but suggests there are underlying factors responsible for the apparent reversal of relationships observed when traditional variables are analyzed in ESRD. For example, in a hypothetical model adjusting for malnutrition, the direction of the relationship of cholesterol and mortality reverses [24]. It is conceivable that cardiovascular risk factors, as we understand them in the general population, behave quite differently in ESRD due to reverse causation [24]. Similar relationships may apply to tHcy as well, whereas a marker that remains constant over a lifespan, such as the TT genotype, would not experience this relationship.

Fifth, should the observation that dialysis patients with prevalent CVD have lower levels of tHcy than those without a history of CVD represent a refutation of the hypothesis that tHcy plays a role in vascular pathogenesis? While this study is not designed to answer the question, it can lend credence to the assertion that tHcy represents a marker for other factors that are important in vascular pathophysiology, rather than a causative agent. Not all epidemiologic studies in the general population and clinical studies in ESRD have supported an association between homocysteine and CVD. Prospective case-cohort analyses from three large-scale community and population studies, The Atherosclerosis Risk in Communities Study [25], a nine-year Finnish study [26], a report from the U.S. Physicians Health Study [27], as well as a meta-analysis of 36 studies [6] have failed to find an association. Cross-sectional studies in ESRD have reported conflicting associations [10, 11, 28–30], and case-control studies may inflate an association by selection of non-ESRD controls [31]. A study of 73 ESRD patients followed for 17 months was only able to adjust for one covariate at a time [32]. Another 17-month study of 167 patients with ESRD on dialysis found the

relative risk for CVD to be 1.01 per 1 $\mu\text{mol/L}$ increase in tHcy, with a 95% confidence interval that included 1.00 [33]. Larger, prospective studies are needed in ESRD to address important questions about the causal role of homocysteine and clinical trials are needed in both ESRD and the general population to establish tHcy as a modifiable risk factor.

Previous studies have shown that the prevalence of the TT genotype remains stable across age groups in the general population [34, 35], and that the superior survival of African Americans and Asians compared with whites in the United States has yet to be fully explained [36, 37]. Unlike some of these studies in the general population, our results support the assertion that the presence of the TT genotype impairs survival in ESRD patients and may be associated with racial differences in survival. This is evidenced by the finding that the prevalence of the TT genotype is decreased in those with greater than one-year duration of dialysis. A recent study of 545 Japanese hemodialysis patients reported similar findings with respect to survival, despite a clinically and demographically different population [7]. Compared with our sample of U.S. dialysis patients, their patients were younger, had lower levels of comorbidity, and were presumably racially homogeneous. Furthermore, the mean age of their patients with TT genotypes was lower than the other two genotypes. However, our data mirrored these Japanese findings when whites (non-Hispanic and Hispanic) were excluded from the analysis by showing a trend toward older age in the TT genotype. Our findings of decreased prevalence of the TT genotype after a one-year duration of dialysis, and the fact that 93% of those with the TT genotype were white suggests that the TT genotype may be a contributor to mortality in white dialysis patients and may partially explain racial differences in survival in U.S. hemodialysis patients.

This investigation has implications for further study in other ethnic groups. To our knowledge, this study represents the only determination of C677T genotypes of MTHFR in Hispanic dialysis patients residing in the United States. The relatively large prevalence of the TT genotype, 23.4%, should be confirmed by other studies. This is especially relevant given the epidemic of type II diabetes and the high prevalence of ESRD in this group [38, 39].

The finding that the C677T mutation of MTHFR is associated with CVD and possibly decreased duration of dialysis in white patients supports the hypothesis that abnormal homocysteine metabolism is a risk factor for atherosclerotic disease. Genetic assessment of MTHFR status may offer a more reliable indication of CVD risk and help direct preventive therapy as those with the TT genotype and below median folate levels may benefit the most from homocysteine reduction. Our study also found that tHcy levels were inversely associated with

CVD. This description of this association is limited due to factors such as survivor bias, confounding by malnutrition or inflammation as seen with other cardiovascular risk factors in ESRD, or the possibility that tHcy is not a causative risk factor in ESRD. tHcy levels obtained after the onset of ESRD may not accurately represent the lifetime tHcy exposure and the C677T genotype may be a more meaningful marker of abnormal homocysteine metabolism in ESRD. Prospective data from ongoing clinical trials are needed to improve our understanding of this finding.

ACKNOWLEDGMENTS

Dr. Wrone was supported by a National Institutes of Health Training Grant DK 07357-16A to the Division of Nephrology, Department of Medicine, Stanford University School of Medicine from July 1997 through June 1999. These data were presented in abstract form at the American Society of Nephrology 32nd Annual Meeting (Miami, FL, USA) in November 1999. The authors express appreciation for the technical assistance of the following: Marilyn Aaron, R.D., C.S., Pauline Auyeung, M.S., R.D., Syd Belanger, R.D., Judy Boccanfuso, R.D., Kathryn Cefaloni, R.D., Trudy O'Regan Esrey, R.D., Marianne Hutton, R.D., Carolyn Kinder, R.D., M.S., Carol Jones, B.A., Cyndi Langford, R.D., Leanne Maru, R.D., Hema Master, R.D., Kathleen O'Connor, R.N., Lynnette Schlick, R.D., Faith Tootell, M.S., R.D., Marty Torres, R.D., Susan Weakley, M.S., R.D., and Carol Wolf, M.S., R.D., C.S.

Reprint requests to Elizabeth Wrone, M.D., Stanford Center for Research in Disease Prevention, 1000 Welch Road, Palo Alto, California 94304-1825, USA.

E-mail: ewrone@stanford.edu

REFERENCES

- MUDD SH, FINKELSTEIN JD, REFSUM H, et al: Homocysteine and its disulfide derivatives: A suggested consensus terminology. *Arterioscler Thromb Vasc Biol* 20:1704-1706, 2000
- FROSST P, BLOM HJ, MILOS R, et al: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. *Nat Genet* 10:111-113, 1995
- FLETCHER O, KESSLING AM: MTHFR association with arteriosclerotic vascular disease? *Hum Genet* 103:11-21, 1998
- HARMON DL, WOODSIDE JV, YARNELL JW, et al: The common "thermolabile" variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia. *Q J Med* 89:571-577, 1996
- MOTTI C, GNASSO A, BERNARDINI S, et al: Common mutation in methylenetetrahydrofolate reductase: Correlation with homocysteine and other risk factors for vascular disease. *Atherosclerosis* 139:377-383, 1998
- BRATTSTROM L, WILCKEN DE, OHRVIK J, BRUDIN L: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis. *Circulation* 98:2520-2526, 1998
- KIMURA H, GEJYO F, SUZUKI S, MIYAZAKI R: The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients. *J Am Soc Nephrol* 11:885-893, 2000
- VYCHYTL A, FODINGER M, WOLFL G, et al: Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. *Kidney Int* 53:1775-1782, 1998
- MCQUILLAN BM, BEILBY JP, NIDORF M, et al: Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening: The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). *Circulation* 99:2383-2388, 1999
- BOSTOM AG, SHEMIN D, LAPANE KL, et al: Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. *Atherosclerosis* 123:193-202, 1996

11. CHAUVEAU P, CHADEFaux B, COUDE M, et al: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. *Kidney Int* 43(Suppl 41):S72–S77, 1993
12. MAKOFF R, DWYER J, ROCCO MV: Folic acid, pyridoxine, cobalamin, and homocysteine and their relationship to cardiovascular disease in end-stage renal disease. *J Renal Nutr* 6:2–11, 1996
13. VAN GULDENER C, DONKER AJ, JAKOBS C, et al: No net renal extraction of homocysteine in fasting humans. *Kidney Int* 54:166–169, 1998
14. U.S. RENAL DATA SYSTEM: *USRDS 2000 Annual Data Report*. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000
15. EMERY A: *Methodology in Medical Genetics: An Introduction to Statistical Methods*. Edinburgh, Churchill Livingstone, 1976, pp 3–9
16. SULIMAN ME, QURESHI AR, BARANY P, et al: Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. *Kidney Int* 57:1727–1735, 2000
17. BRULEZ HF, VAN GULDENER C, DONKER AJ, TER WEE PM: The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. *Nephrol Dial Transplant* 14:154–159, 1999
18. BERGSTROM J, LINDHOLM B: Malnutrition, cardiac disease, and mortality: An integrated point of view. *Am J Kidney Dis* 32:834–841, 1998
19. BLACK HR: Optimal blood pressure: How low should we go? *Am J Hypertens* 12:113S–120S, 1999
20. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. *Arch Intern Med* 160:898–904, 2000
21. ZAGER PG, NIKOLIC J, BROWN RH, et al: “U” curve association of blood pressure and mortality in hemodialysis patients: Medical Directors of Dialysis Clinic, Inc. *Kidney Int* 54:561–569, 1998
22. LEAVEY SF, STRAWDERMAN RL, JONES CA, et al: Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. *Am J Kidney Dis* 31:997–1006, 1998
23. LOWRIE EG, LEW NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. *Am J Kidney Dis* 15:458–482, 1990
24. CORESH J, LONGENECKER JC, MILLER ER III, et al: Epidemiology of cardiovascular risk factors in chronic renal disease. *J Am Soc Nephrol* 9(Suppl):S24–S30, 1998
25. FOLSOM AR, NIETO FJ, MCGOVERN PG, et al: Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 98:204–210, 1998
26. ALFTHAN G, PEKKANEN J, JAUHAINEN M, et al: Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. *Atherosclerosis* 106:9–19, 1994
27. VERHOEF P, HENNEKENS CH, ALLEN RH, et al: Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. *Am J Cardiol* 79:799–801, 1997
28. MANN BJ, BURGESS ED, HYNDMAN ME, et al: Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. *Am J Kidney Dis* 34:669–677, 1999
29. ROBINSON K, GUPTA A, DENNIS V, et al: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. *Circulation* 94:2743–2748, 1996
30. BACHMANN J, TEPEL M, RAIDT H, et al: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. *J Am Soc Nephrol* 6:121–125, 1995
31. BOSTOM AG, SHEMIN D, LAPANE KL, et al: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. *Atherosclerosis* 114:93–103, 1995
32. BOSTOM AG, SHEMIN D, VERHOEF P, et al: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. *Arterioscler Thromb Vasc Biol* 17:2554–2558, 1997
33. MOUSTAPHA A, NASO A, NAHLAWI M, et al: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. *Circulation* 97:138–141, 1998
34. BRATTSTROM L, ZHANG Y, HURTIG M, et al: A common methylenetetrahydrofolate reductase gene mutation and longevity. *Atherosclerosis* 141:315–319, 1998
35. HERRMANN W, QUAST S, ULLRICH M, et al: Hyperhomocysteinemia in high-aged subjects: Relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutation. *Atherosclerosis* 144:91–101, 1999
36. The USRDS and its products: United States Renal Data System. *Am J Kidney Dis* 32:S20–S37, 1999
37. WONG JS, PORT FK, HULBERT-SHEARON TE, et al: Survival advantage in Asian American end-stage renal disease patients. *Kidney Int* 55:2515–2523, 1999
38. PUGH JA: Diabetic nephropathy and end-stage renal disease in Mexican Americans. *Blood Purif* 14:286–292, 1996
39. BURKE JP, WILLIAMS K, GASKILL SP, et al: Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: Results from the San Antonio Heart Study. *Arch Intern Med* 159:1450–1456, 1999